Cargando…

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Detalles Bibliográficos
Autores principales: Gutteridge, Eleanor, Robertson, John FR
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797704/
https://www.ncbi.nlm.nih.gov/pubmed/20030876
http://dx.doi.org/10.1186/bcr2443
_version_ 1782175657998942208
author Gutteridge, Eleanor
Robertson, John FR
author_facet Gutteridge, Eleanor
Robertson, John FR
author_sort Gutteridge, Eleanor
collection PubMed
description
format Text
id pubmed-2797704
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27977042009-12-25 Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors Gutteridge, Eleanor Robertson, John FR Breast Cancer Res Short Communication BioMed Central 2009 2009-12-18 /pmc/articles/PMC2797704/ /pubmed/20030876 http://dx.doi.org/10.1186/bcr2443 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Short Communication
Gutteridge, Eleanor
Robertson, John FR
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
title Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
title_full Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
title_fullStr Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
title_full_unstemmed Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
title_short Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors
title_sort are current drug development programmes realising the full potential of new agents? tyrosine kinase inhibitors
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797704/
https://www.ncbi.nlm.nih.gov/pubmed/20030876
http://dx.doi.org/10.1186/bcr2443
work_keys_str_mv AT gutteridgeeleanor arecurrentdrugdevelopmentprogrammesrealisingthefullpotentialofnewagentstyrosinekinaseinhibitors
AT robertsonjohnfr arecurrentdrugdevelopmentprogrammesrealisingthefullpotentialofnewagentstyrosinekinaseinhibitors